<SEC-DOCUMENT>0001437749-24-022528.txt : 20240711
<SEC-HEADER>0001437749-24-022528.hdr.sgml : 20240711
<ACCEPTANCE-DATETIME>20240711085019
ACCESSION NUMBER:		0001437749-24-022528
CONFORMED SUBMISSION TYPE:	FWP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20240711
DATE AS OF CHANGE:		20240711

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NovaBay Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001389545
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				680454536
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		FWP
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-280423
		FILM NUMBER:		241111109

	BUSINESS ADDRESS:	
		STREET 1:		2000 POWELL STREET, SUITE 1150
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
		BUSINESS PHONE:		(510) 899-8800

	MAIL ADDRESS:	
		STREET 1:		2000 POWELL STREET, SUITE 1150
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NovaBay Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001389545
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				680454536
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		FWP

	BUSINESS ADDRESS:	
		STREET 1:		2000 POWELL STREET, SUITE 1150
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
		BUSINESS PHONE:		(510) 899-8800

	MAIL ADDRESS:	
		STREET 1:		2000 POWELL STREET, SUITE 1150
		CITY:			EMERYVILLE
		STATE:			CA
		ZIP:			94608
</SEC-HEADER>
<DOCUMENT>
<TYPE>FWP
<SEQUENCE>1
<FILENAME>nby20240711_fwp.htm
<DESCRIPTION>FORM FWP
<TEXT>
<html><head>
	<title>nby20240711_fwp.htm</title>

	<!-- Generated by ThunderDome Portal - 7/11/2024 5:12:11 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Filed Pursuant to Rule 433 of the Securities Act of 1933</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Issuer Free Writing Prospectus dated July 11, 2024</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Registration Statement No. 333-280423</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div><img alt="logo.jpg" src="logo.jpg"></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NovaBay Pharmaceuticals Reports Preliminary Second Quarter 2024 Net Revenue </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>of $2.4 Million </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>Eyecare revenue for both the second quarter and the first half of 2024 increased by 9% over the comparable prior-year periods, driven by higher online sales</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>The number of Avenova</i>&#174;<i> subscribers on Amazon increased by 64% since the beginning of 2023 and by 123% since the beginning of 2022</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>EMERYVILLE, Calif.</b> <b>(July 11, 2024)</b> &#8211; NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) (the &#8220;Company&#8221; or &#8220;NovaBay&#8221;) announces preliminary net revenue for the second quarter of 2024 of $2.4 million and for the first half of 2024 of $5.0 million, primarily derived from the Company&#8217;s eyecare products. Net revenue from the Company&#8217;s eyecare products increased by 9% for both the second quarter and the first half of 2024 over the corresponding periods in 2023. NovaBay also expects 2024 net revenue from the Company&#8217;s eyecare products to be approximately $10 million.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#8220;The increase in eyecare net revenue so far this year was driven by higher sales of Avenova-branded products through online channels. We benefitted from growth in Avenova sales due to our loyal Amazon and Avenova.com subscribers with our subscriber base accounting for approximately 23% of all online Avenova revenue for the first half of this year,&#8221; said Justin Hall, CEO of NovaBay.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#8220;Growth in our subscriber base is critical to our business success because these loyal customers generate consistent sales that we can build upon through our cost-efficient digital marketing programs. In fact, even with this year&#8217;s expected revenue growth, we anticipate a slight year-over-year decline in sales and marketing expenses,&#8221; he added. &#8220;Our ability to consistently grow our base underscores our belief that first-time consumers who use our high-quality Avenova products typically return as satisfied repeat customers. This further supports NovaBay&#8217;s strategic focus on the large, growing U.S. dry eye market.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The number of Avenova subscribers on Amazon, the Company&#8217;s largest sales channel, increased 16% during the first six months of 2024 and is up 123% since the beginning of 2022. In addition, of the more than 14,000 customer ratings across all online channels, Avenova Lid &amp; Lash Solution averages an impressive 4.5-star overall rating.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">NovaBay offers a full portfolio of scientifically developed products for each step of the standard dry eye treatment regimen. These include Avenova Lid &amp; Lash Solution, prescribed hypochlorous acid product for eyelid and eyelash cleansing, Avenova Eye Health Support antioxidant-rich oral supplement, Avenova Lubricating Eye Drops for instant relief, Avenova Warm Eye Compress to soothe the eyes and the i-Chek by Avenova to monitor physical eyelid health. The Avenova Allograft, an amniotic tissue prescription-only product, is available through eyecare professionals in the U.S.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>About NovaBay Pharmaceuticals, Inc.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">NovaBay&#8217;s leading product Avenova&#174; Antimicrobial Lid &amp; Lash Solution is often prescribed by eyecare professionals for blepharitis and dry eye disease. Manufactured in the U.S., Avenova spray is formulated with NovaBay's patented, proprietary, stable and pure form of hypochlorous acid. It is clinically proven to kill a broad spectrum of bacteria to help relieve the symptoms of bacterial dry eye, yet is non-irritating and completely safe for regular use. All Avenova products are available directly to consumers through online distribution channels such as Amazon.com and Avenova.com.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Notice</b></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">NovaBay filed a registration statement on Form S-1 (File No. 333-280423) (the &#8220;Registration Statement&#8221;) with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;), including a preliminary prospectus dated July 10, 2024 (the &#8220;Preliminary Prospectus&#8221;), with the SEC relating to its proposed offer and sale of securities of NovaBay (the &#8220;offering&#8221;); however, the Registration Statement has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the Registration Statement becomes effective.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">This press release does not constitute an offer to sell, nor a solicitation of an offer to buy, any securities by any person in any jurisdiction in which it is unlawful for such person to make such an offering or solicitation. Neither the SEC nor any other regulatory body has approved or disapproved of our securities or passed upon the accuracy or adequacy of this press release. Any representation to the contrary is a criminal offense. Before you invest, you should read the Preliminary Prospectus (including the risk factors described therein) in the Registration Statement and, when available, the final prospectus relating to the offering, and the other documents we have filed with the SEC, for more complete information about the Company and the offering. You may obtain these documents, including the Preliminary Prospectus, for free by visiting EDGAR on the SEC website at http://www.sec.gov. A copy of the preliminary prospectus is also available at:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1389545/000143774924022434/nby20240709_s1a.htm" style="-sec-extract:exhibit;">https://www.sec.gov/Archives/edgar/data/1389545/000143774924022434/nby20240709_s1a.htm</a></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Alternatively, copies of the Preliminary Prospectus may be obtained, when available, from: Ladenburg Thalmann &amp; Co. Inc. by written request addressed to Syndicate Department, 640 5th Avenue, 4th Floor, New York, NY 10019 (telephone number 1-800-573-2541) or by emailing <u>prospectus@ladenburg.com</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Forward-Looking Statements</b>&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This press release contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, but not limited to, statements that are based upon management's current expectations, assumptions, estimates, projections and beliefs. The use of words such as, but not limited to, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," &#8220;preliminary,&#8221; "should," "target," "will," or "would" and similar words or expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding our business strategies, current and projected revenue sources, expected future revenue, customer loyalty and satisfaction, as well as generally the Company&#8217;s expected future financial results. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Other risks relating to the Company&#8217;s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in the Company&#8217;s latest Form 10-Q/K filings and Registration Statement, as may be amended from time to time, filing with the SEC, especially under the heading &#8220;Risk Factors.&#8221; The forward-looking statements in this release speak only as of this date, and the Company disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><u>Socialize and Stay Informed on NovaBay</u></b><u>&#8217;</u><b><u>s Progress</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Like us on&nbsp;<u>Facebook</u></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Follow us on&nbsp;<u>X</u></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Connect with NovaBay on&nbsp;<u>LinkedIn</u></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Visit NovaBay's&nbsp;<u>Website</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><u>Avenova Purchasing Information</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For NovaBay Avenova purchasing information:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Please call 800-890-0329 or email&nbsp;<u>sales@avenova.com</u></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>Avenova.com</u></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><u>NovaBay Contact</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Justin Hall</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Chief Executive Officer and General Counsel</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">510-899-8800</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>jhall@novabay.com</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><u>Investor Relations Contact</u></b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">LHA Investor Relations</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Jody Cain</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">310-691-7100</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><u>jcain@lhai.com</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"># # #</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
M   *    &@    !'<F5E;G-H;W0 _]L 0P '!04&!00'!@4&" <'" H1"PH)
M"0H5#Q ,$1@5&AD8%1@7&QXG(1L=)1T7&"(N(B4H*2LL*QH@+S,O*C(G*BLJ
M_]L 0P$'" @*"0H4"PL4*AP8'"HJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ_\  $0@ *@#B P$B  (1 0,1 ?_$
M !\   $% 0$! 0$!           ! @,$!08'" D*"__$ +40  (! P,"! ,%
M!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A""-"L<$54M'P)#-B<H()
M"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T
M=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%
MQL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$!
M 0$! 0$        ! @,$!08'" D*"__$ +41  (! @0$ P0'!00$  $"=P !
M @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:
M)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#
MA(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3
MU-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ ]R\1>-]
M\*7$$.NWWV:2=2\8\MFW '!Z U1TSXH^$-7U*"PL=75[FX;;&K1NNX^F2,5Y
MG^T-_P AS1?^O>3_ -"%>/JS(ZNC%64@JP."".A%>K1P4*M)3;=V>17QTZ55
MPMHC[2OKV#3K">]O'\N"WC,DCXSM4#)/%<E!\7/!=S<10PZQNDE<(@\B3DDX
M':N<T#QXOC'X2ZU!>N/[5LK"1;A?^>B[#B0?7O[UX1H?_(?TS_K[A_\ 0Q44
M<&I<RGNC6MC7'D<-5(^OM8UB#1[5))5:6:9Q'! F-TKGG STX!))X !->/\
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M/F;,9X; W=,5U=%5SZ[$\FEKG%>*8-9EUF]FTU9#'!8QM&PE=2K[WR4"\,V
M.#[5H>)[B_M;C2KRP6YE2W:26>*$']ZH3[I'KSD#U%=+11S[:;!R;ZG-:--J
M.G>%KZ>^%Q=7D<LKJC@EF)Y50/3)Q3_"#:I%9W%CKD<PN() RR22>9O5QNX;
MOAMPQV&*Z*BDYW3TW&HV:UV/E+7]$\9W^IW*7FGZU=0K<2&%94D=0-QP1GVK
MT_X*> K_ $22ZUS7;1K6XE3R;:*48=4ZLQ';/ _"O7J*ZZF,E.GR)6.2G@H0
0J>T;NPHHHKA.X**** /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
